Overview
Semaglutide activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, reduced caloric intake.
Related guides
- 503A vs 503B Compounding Pharmacies Explained
- Semaglutide Cost Guide — Brand vs Compounded Pricing
- Semaglutide Side Effects — What Patients Report
- Semaglutide Dosing Schedule
- BMI Eligibility for Semaglutide Weight Management
- Compounded vs Brand-Name Semaglutide
- Semaglutide Insurance Coverage
- Semaglutide and Cardiovascular Health
Key facts, checked November 20, 2026
Per the Wegovy label, semaglutide is a GLP-1 analogue that activates the GLP-1 receptor, including in brain regions that regulate appetite and food intake, and it slows gastric emptying. In STEP 1 (NEJM 2021), that translated into 14.9% average weight loss at 68 weeks on 2.4 mg weekly, against 2.4% on placebo. The label says the exact mechanism of its cardiovascular benefit has not been established. Compounded semaglutide is not FDA-approved and was not the product tested, as FDA’s page on unapproved GLP-1 drugs notes.